Soleno Therapeutics (SLNO) Gains from Sales and Divestitures (2016 - 2026)
Soleno Therapeutics (SLNO) reported Gains from Sales and Divestitures of $84850.0 for Q1 2026, down 89.4% year-over-year from $800500.0 in Q1 2025, and down 90.44% quarter-over-quarter from $887124.0 in Q4 2025.
Soleno Therapeutics (SLNO) Gains from Sales and Divestitures (2016 - 2026) Analysis & Trends
Soleno Therapeutics (SLNO) has 9 years of Gains from Sales and Divestitures data on file, last reported at $84850.0 in Q1 2026.
- Gains from Sales and Divestitures for Q1 2026 came in at $84850.0, down 89.4% year-over-year; the trailing twelve-month figure through Mar 2026 was $84850.0 (down 89.4% YoY), and the FY2025 annual result was $887124.0, down 18.49% from the prior year.
- Gains from Sales and Divestitures fell to $84850.0 in Q1 2026 per SLNO's latest filing, from $887124.0 in the prior quarter.
- Over five years, Gains from Sales and Divestitures peaked at $1.1 million in Q4 2024 and troughed at $9534.0 in Q1 2023.
- A 5-year average of $392023.1 and a median of $279757.0 in 2022 frame the typical range for Gains from Sales and Divestitures.
- The sharpest annual moves came in 2023 and 2024: Gains from Sales and Divestitures slumped 96.59% in 2023, then jumped 9869.94% in 2024.
- A 5-year view of Gains from Sales and Divestitures shows it stood at $18646.0 in 2022, then jumped by 2169.91% to $423248.0 in 2023, then jumped by 157.13% to $1.1 million in 2024, then declined by 18.49% to $887124.0 in 2025, then slumped by 90.44% to $84850.0 in 2026.
- Business Quant data shows SLNO's Gains from Sales and Divestitures at $84850.0 in Q1 2026, $887124.0 in Q4 2025, and $825607.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Soleno Therapeutics | 2.76 Bn | 2.51 Bn | 93.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 84,850.00 |
| Mar 31, 2026 | 84,850.00 |
| Dec 31, 2025 | 887,124.00 |
| Dec 31, 2025 | 887,124.00 |
| Sep 30, 2025 | 825,607.00 |
| Sep 30, 2025 | 825,607.00 |
| Jun 30, 2025 | 819,273.00 |
| Jun 30, 2025 | 819,273.00 |
| Mar 31, 2025 | 800,500.00 |
| Mar 31, 2025 | 800,500.00 |
| Dec 31, 2024 | 1.09 Mn |
| Dec 31, 2024 | 1.09 Mn |
| Sep 30, 2024 | 950,534.00 |
| Sep 30, 2024 | 950,534.00 |
| Jun 30, 2024 | 74,250.00 |
| Jun 30, 2024 | 74,250.00 |
| Mar 31, 2024 | 85,284.00 |
| Mar 31, 2024 | 85,284.00 |
| Dec 31, 2023 | 423,248.00 |
| Dec 31, 2023 | 423,248.00 |